Disease Areas
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Genetron Health Partners with Guizhou Local Government for Liver Cancer Early Screening Project
The firm will provide testing using its HCCscreen assay and help develop follow-up procedures as part of an effort to advance cancer early detection in rural areas of China.
Merck's Keytruda Nets Two FDA Full Approvals in Triple-Negative Breast Cancer
The PD-1 inhibitor is now approved as neoadjuvant and adjuvant therapy for high-risk early-stage TNBC, as well as for later-stage, PD-L1-high TNBC patients with chemo.